- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01802892
Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)
The present study aims to evaluate the impact of 5 days oral administration of ronacaleret 100 miligram (mg) and 400 mg on changes in circulating CD34+ cells, when ronacaleret is followed by the administration of a single dose of plerixafor in healthy human volunteers.
This single centre adaptive design study will be carried out in 2 parts. The part A will evaluate the change in peripheral circulating CD34+ cells in response to two different 5 day regimens of ronacaleret (100 mg or 400 mg once daily), given in conjunction with a single dose of plerixafor (0.24 mg/kilogram [kg]) sub-cutaneously (SC) on the evening of the final days dosing approximately 12 hours before collection of CD34+ cells on day 6. Subjects (5 each) will be assigned to either one of the ronacaleret arms, in an open fashion. Comparisons will be made in the change from baseline to end of treatment peripheral CD34+ cell counts. Part A will be conducted in two cohorts with 5 subjects being enrolled into each of the 2 treatment arms making up the first cohort. Cohort 2 will involve up to 5 further subjects being enrolled into each treatment arm.
The structure of part B will be finalized following a review of data generated in part A.
The total study duration of Part A for each subject including the screening, treatment and follow-up periods will be approximately 7 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66211
- GSK Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- A male or female between 18 and 65 years of age (inclusive).
- Healthy as determined by a physician, based on a medical evaluation and with an estimated Glomerular Filtration Rate (GFR) of >=60 mL/min /1.73 m^2 using the four variable Modification of Diet in Renal Disease (MDRD) equation.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Female of non-child bearing potential, or female subjects and male subjects with female partners of child-bearing potential willing to use protocol-specified methods of contraception to prevent pregnancy during the study.
- Body weight of 55 kg or more and body mass index (BMI) of 20.0 to 35.0 kg/m^2 (inclusive).
- Capable of giving written informed consent.
Exclusion Criteria:
- A positive pre-study drug/alcohol screen.
- A positive test for HIV, B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- History of or therapy for osteoporosis
- Subject has had treatment for any condition relating to the thyroid/parathyroid gland which in the opinion of the investigator may influence the subjects production of PTH
- Subjects with any contraindications or know allergies to receiving plerixafor
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
- Subjects taking calcium and/or vitamin D supplements, during or within 2 weeks of study initiation
- Subjects taking any concomitant medications
- Specific laboratory abnormalities at screening like Serum calcium (total or albumin-adjusted) outside the central laboratory reference range, PTH outside the normal range, Creatine phosphokinase (CPK) outside the normal range
- Subjects with abnormal Vitamin D (Vitamin D, 25-Hydroxy) levels may be enroled if repeat lab results, obtained within 14 days of initial screening assessments, are within the normal range
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females.
- Lactating or pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test at screening or prior to dosing.
- The subject has participated in a clinical trial within 30 days or 5 half-lives of the IP prior to the first dosing day in the current study.
- Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Ronacaleret 100 mg
Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
|
Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
|
Expérimental: Ronacaleret 400 mg
Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
|
Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Mean change from baseline in CD34+ cell counts
Délai: Baseline and upto Day 14
|
The mean fold change from baseline in the number of circulating CD34+ cells for all treatment arms will be assessed.
Samples will be collected at screening, Day 4 and Day 5 (2 hrs post ronacaleret dose), Day 6 (12 hrs and 14 and 16 hrs post plerixafor dose) and Day 14
|
Baseline and upto Day 14
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Spontaneous AE reporting
Délai: Up to 14 days
|
Adverse events (AEs) will be collected from the start of Investigation Product (IP) and until the follow-up visit
|
Up to 14 days
|
Clinical laboratory safety data
Délai: Up to 14 days
|
Clinical laboratory tests will include hematology, clinical chemistry and urinalysis
|
Up to 14 days
|
Measure of vital signs to access safety and tolerability
Délai: Up to 14 days
|
Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.
Subjects should have been in a supine or semi-supine (recumbent) position for at least 5 minutes prior to taking measurements
|
Up to 14 days
|
PTH responses
Délai: Up to 6 days
|
Parathyroid hormone (PTH) has been shown to stimulate osteoblasts and osteoclasts and also associated with increased numbers of circulating CD34+ve cells
|
Up to 6 days
|
Quantification of the number of stem cells
Délai: Part B will be detailed in an amendment to the protocol following a data review of part A
|
The number of stem cells from the various hematopoietic lineages through colony forming unit assays in Part B of the study
|
Part B will be detailed in an amendment to the protocol following a data review of part A
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 116610
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Transplantation, cellule souche
-
Rutgers, The State University of New JerseyComplétéMBSR-STIM | PMR-STEM | MBSR-NON-STEM | PMR -NON STEMÉtats-Unis
-
Abramson Cancer Center of the University of PennsylvaniaRetiréPatients cancéreux subissant une greffe de cellules souches (RCT of ACP for Transplant)
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesRecrutementÉligible en hématopathologie ou traitement CAR-t CellFrance
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRecrutementMesures des résultats rapportés par les patients | Thérapie CAR T-CellSuisse
-
Dartmouth-Hitchcock Medical CenterComplétéLymphome | Leucémie | Myélome multiple | Greffe de cellules souches | Greffe de cellules souches hématopoïétiques | Thérapie CAR T-Cell | GCSH | Thérapie cellulaire | Transplantation CAR T-CellÉtats-Unis
-
Shenzhen Fifth People's HospitalRecrutement
-
Manchester University NHS Foundation TrustUniversity of Manchester; The Christie NHS Foundation Trust; Zenzium AI Ltd.; Aptus... et autres collaborateursRecrutementCancer colorectal | Cancer du poumon | Cancer hématologique | Thérapie CAR T-CellRoyaume-Uni
-
Sun Yat-sen UniversityPas encore de recrutementCancer du col de l'utérus | Effet de la chimiothérapie | Thérapie néoadjuvante | Programmed Cell Death 1 Receptor / Antagonistes et inhibiteurs
-
University of Alabama at BirminghamRésiliéLymphome anaplasique à grandes cellules | Lymphome T angio-immunoblastique | Lymphomes T périphériques | Leucémie à cellules T de l'adulte | Lymphome T adulte | Lymphome T périphérique Non précisé | T/Null Cell Systemic Type | Lymphome cutané à cellules T avec maladie nodale/viscéraleÉtats-Unis
-
Adelphi Values LLCBlueprint Medicines CorporationComplétéLeucémie mastocytaire (MCL) | Mastocytose systémique agressive (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Mastocytose systémique fumante (SSM) | Mastocytose systémique indolente (ISM) Sous-groupe ISM entièrement recrutéÉtats-Unis
Essais cliniques sur Ronacaleret 100 mg
-
OrthoTrophix, IncComplété
-
AstraZenecaComplétéAntagoniste du récepteur de chimiokine 2 (CXCR2)Royaume-Uni
-
NEURALIS s.a.RecrutementPharmacocinétique | SécuritéBulgarie
-
JW PharmaceuticalComplétéDysérectionCorée, République de
-
Juventas Therapeutics, Inc.ComplétéIschémie critique des membresÉtats-Unis, Inde
-
Hospices Civils de LyonGlaxoSmithKlineRecrutement
-
AstraZenecaComplété
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.ComplétéDiabète sucré de type 2Chine
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldRecrutement
-
Medical Centre LeeuwardenGlaxoSmithKlineComplété